Home Font Size: 1 2 3 Send to a Friend

News & Events

Morphotek, Inc. Announces a Licensing Deal with Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody

October 28, 2009

...

+ Read the Article

Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects

September 24, 2009

...

+ Read the Article

Morphotek, Inc. Awarded Funding to Develop Therapeutic Antibodies Against Potential Biowarfare Toxins

September 23, 2009

...

+ Read the Article

Ovarian Cancer Patients Given True Gift of Happiness

August 25, 2009

...

+ Read the Article

Morphotek, Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies

July 15, 2009

...

+ Read the Article

Morphotek, Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease

July 1, 2009

...

+ Read the Article

Morphotek, Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, A Monoclonal Antibody for the Treatment of Cancer

June 9, 2009

...

+ Read the Article

Morphotek, Inc and Lonza Group LTD Enter Into Manufacturing Services Agreement

May 19, 2009

...

+ Read the Article

Human Genome Sciences and Morphotek, Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology

March 25, 2009

...

+ Read the Article

Morphotek, Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer

March 23, 2009

...

+ Read the Article

Go to Page: 1 2 3 4 5 6 7 8 9 10

Results per page 10 25 50

©2005 Morphotek Inc. | 210 Welsh Pool Road | Exton, PA 19341 | (610) 423-6100 Privacy Policy | Site Map | Contact Us